SCHEMBL1765291

SCHEMBL1765291

COc1cccc(-c2oc3ccccc3c(=O)c2OC)c1OC

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.84
CYP3A4 P08684 6/20 0.84
HSD17B10 Q99714 5/20 0.84
TSHR P16473 4/20 0.84
CYP2C9 P11712 3/20 0.84
CYP2C19 P33261 3/20 0.84
ABCG2 Q9UNQ0 4/20 0.65
ALDH1A1 P00352 6/20 0.63
MEN1 O00255 5/20 0.63
KMT2A Q03164 5/20 0.63
HPGD P15428 5/20 0.63
MAOA P21397 3/20 0.58
NPC1 O15118 3/20 0.57
LMNA P02545 2/20 0.57
RAB9A P51151 2/20 0.57
NTRK1 P04629 1/20 0.52
PLK3 Q9H4B4 1/20 0.52
MAPT P10636 4/20 0.50
ALOX15 P16050 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL380906 0.92 KDM4E (1.00) KDM4ECYP3A4HSD17B10TSHRCYP2C9
SCHEMBL4649956 0.89 KDM4E (0.80) KDM4ECYP3A4HSD17B10TSHRCYP2C9
SCHEMBL774316 0.89 KDM4E (0.75) KDM4ECYP3A4HSD17B10TSHRCYP2C9
SCHEMBL5796787 0.84 KDM4E (0.65) KDM4ECYP3A4HSD17B10TSHRCYP2C9
SCHEMBL23883097 0.83 CYP2C9 (0.63) KDM4ECYP3A4HSD17B10TSHRCYP2C9
SCHEMBL8854752 0.82 KDM4E (0.72) KDM4ECYP3A4HSD17B10TSHRCYP2C9
SCHEMBL29727380 0.82 KDM4E (0.72) KDM4ECYP3A4HSD17B10TSHRCYP2C9
SCHEMBL253523 0.79 ABCG2 (1.00) KDM4ECYP3A4HSD17B10TSHRCYP2C9
SCHEMBL29993383 0.79 ABCG2 (1.00) KDM4ECYP3A4HSD17B10TSHRCYP2C9
SCHEMBL9527476 0.79 KDM4E (0.76) KDM4ECYP3A4HSD17B10TSHRCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117561081-A Application of CYP450 inhibitor in inhibiting or killing mites and treating xerophthalmia 广州珍实视界生物医药科技有限公司 2024-02-13 CN claimed
EP-4258899-A1 HYDROXY- AND METHOXY-SUBSTITUTED FLAVONES AND THEIR USE Firmenich SA (CH) 2023-10-18 EP claimed
CN-116249520-A Blocking replication of SARS-COV-2 and other pathogenic viruses using WNT/beta-catenin pathway inhibitors 阿尔伯塔大学理事会 2023-06-09 CN claimed
WO-2022189155-A1 HYDROXY- AND METHOXY-SUBSTITUTED FLAVONES AND THEIR USE FIRMENICH SA (CH) 2022-09-15 WO claimed
CN-114867486-A Composition containing Heijiang extract and oral composition 丸善制药株式会社 2022-08-05 CN claimed
WO-2021050449-A1 COMPOSITIONS AND METHODS OF SUPPRESSING AVERSIVENESS OF PHARMACEUTICALS AND INGESTIBLE MATERIALS MONELL CHEMICAL SENSES CENTER (US) 2021-03-18 WO claimed
CN-106455665-B Black ginger oil extract and preparation method thereof 三得利控股株式会社 2020-06-30 CN claimed
CN-107411083-A Cape jasmine alcohol elution auxiliary improvement of memory capsule or tablet are applied in auxiliary improving memory function health food is prepared 江西中医药大学 2017-12-01 CN claimed
CN-106619674-A Application of effective part or effective component of jasmines in preparation of medicine or health-care food for treating heterogeneitys and multi-factors' alzheimer's diseases 张忠立 2017-05-10 CN claimed
CN-102018740-B Pharmaceutical composition containing sunflower leaf extract and use thereof PEIXUE LING 2012-05-23 CN claimed
EP-1807408-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS Council of Scientific and Industrial Research (IN) 2007-07-18 EP claimed
WO-2006040621-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-04-20 WO claimed
US-20250281559-A1 DRUG FOR TREATMENT OF BREAST CANCER WITH ANTLER AND GINSENG AS SOVEREIGN DRUG AND PREPARATION METHOD AND APPLICATION THEREOF JILIN UNIVERSITY (CN) 2025-09-11 US disclosed
US-20250263774-A1 DISCOVERING NEW XENOBIOTIC SUBSTRATES OF AN UDP-GLYCOSYLTRANSFERASE WITH A HIGH-THROUGHPUT METHOD UNIV NORTH TEXAS (US) 2025-08-21 US disclosed
US-20240389587-A1 COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) (FR) 2024-11-28 US disclosed
US-20240197890-A1 FLAVONE DERIVATIVES AND USES IN TARGETING CK2-MEDIATED DISEASES AND CONDITIONS SALK INSTITUTE FOR BIOLOGICAL STUDIES 2024-06-20 US disclosed
WO-2011157936-A1 COMPOSITIONS CONTAINING FLAVONES AND ANTHELMINTICS INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) 2011-12-22 WO disclosed
US-20110177237-A1 ANTIFOULING METHOD AND COMPOSITION USING CHROMEN-4-ONE DERIVATIVES THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2011-07-21 US disclosed
US-20110124721-A1 METHODS OF TREATING TRAUMATIC BRAIN INJURY BY ADMINISTERING BAICALEIN PREPARATION NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-05-26 US disclosed
US-20100222421-A1 Usage of Baicalein in the Preparation of a Pharmaceutical Composition for the Treatment of Traumatic Brain Injury NATIONAL DEFENSE MEDICAL CENTER (TW) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240389587-A1 COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS XBP1, ERN1, ERN2 KDM4E 2982/4885CYP3A4 2585/4885HSD17B10 1357/4885
US-20240197890-A1 FLAVONE DERIVATIVES AND USES IN TARGETING CK2-MEDIATED DISEASES AND CONDITIONS PACSIN2, CSNK1E, CSNK2A2 KDM4E 2594/4885CYP3A4 2817/4885HSD17B10 2863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.